Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,393 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lenalidomide for myelodysplastic syndromes with del(5q): how long should it last?
Vozella F, Latagliata R, Carmosino I, Volpicelli P, Montagna C, Romano A, Roberto A, Finsinger P, Mancini M, Breccia M, Oliva E, Oliva E. Vozella F, et al. Among authors: mancini m. Hematol Oncol. 2015 Mar;33(1):48-51. doi: 10.1002/hon.2134. Epub 2014 Feb 18. Hematol Oncol. 2015. PMID: 25950027
Familial occurrence of myelodysplastic syndrome with del(5q).
Volpicelli P, Latagliata R, Carmosino I, Breccia M, Vozella F, Mancini M, Cannella L, Alimena G. Volpicelli P, et al. Among authors: mancini m. Leuk Lymphoma. 2011 Jun;52(6):1143-5. doi: 10.3109/10428194.2011.559669. Leuk Lymphoma. 2011. PMID: 21599595 No abstract available.
Impact of exclusion criteria for the DASISION and ENESTnd trials in the front-line treatment of a 'real-life' patient population with chronic myeloid leukaemia.
Latagliata R, Carmosino I, Vozella F, Volpicelli P, De Angelis F, Loglisci MG, Salaroli A, De Luca ML, Montagna C, Serrao A, Molica M, Diverio D, Nanni M, Mancini M, Breccia M, Alimena G. Latagliata R, et al. Among authors: mancini m. Hematol Oncol. 2017 Jun;35(2):232-236. doi: 10.1002/hon.2274. Epub 2015 Dec 9. Hematol Oncol. 2017. PMID: 26648184
Pulmonary infections in patients with myelodysplastic syndromes receiving frontline azacytidine treatment.
Latagliata R, Niscola P, Fianchi L, Aloe Spiriti MA, Maurillo L, Carmosino I, Cesini L, Sarlo C, Piccioni A, Campagna A, De Luca ML, De Benedittis D, Mancini M, Breccia M, Criscuolo M, Buccisano F, Voso MT, Avvisati G, Tafuri A, De Fabritiis P, Foà R, Girmenia C. Latagliata R, et al. Among authors: mancini m. Hematol Oncol. 2020 Apr;38(2):189-196. doi: 10.1002/hon.2710. Epub 2020 Jan 23. Hematol Oncol. 2020. PMID: 31891213
Discontinuation of alpha-interferon treatment in patients with chronic myeloid leukemia in long-lasting complete molecular response.
Latagliata R, Romano A, Mancini M, Breccia M, Carmosino I, Vozella F, Montagna C, Volpicelli P, De Angelis F, Petrucci L, Serrao A, Molica M, Salaroli A, Diverio D, Alimena G. Latagliata R, et al. Among authors: mancini m. Leuk Lymphoma. 2016;57(1):99-102. doi: 10.3109/10428194.2015.1043548. Epub 2015 Oct 5. Leuk Lymphoma. 2016. PMID: 25997497
"Real-life" results of front-line treatment with Imatinib in older patients (≥ 65 years) with newly diagnosed chronic myelogenous leukemia.
Latagliata R, Breccia M, Carmosino I, Cannella L, De Cuia R, Diverio D, Frustaci A, Loglisci G, Mancini M, Santopietro M, Stefanizzi C, Volpicelli P, Vozella F, Alimena G. Latagliata R, et al. Among authors: mancini m. Leuk Res. 2010 Nov;34(11):1472-5. doi: 10.1016/j.leukres.2010.07.001. Epub 2010 Aug 13. Leuk Res. 2010. PMID: 20708799
Independent prognostic impact of CD15 on complete remission achievement in patients with acute myeloid leukemia.
Chisini M, Stefanizzi C, Ceglie T, Raponi S, Vozella F, Colafigli G, Salaroli A, D'Angiò M, Mancini M, Diverio D, Breccia M, Mancini F, Minotti C, Trisolini S, Capria S, Testi AM, Guarini A, Latagliata R, De Propris MS, Foà R. Chisini M, et al. Among authors: mancini m, mancini f. Hematol Oncol. 2017 Dec;35(4):804-809. doi: 10.1002/hon.2331. Epub 2016 Jul 12. Hematol Oncol. 2017. PMID: 27400753
Identification of predictive factors for overall survival at baseline and during azacitidine treatment in high-risk myelodysplastic syndrome patients treated in the clinical practice.
Scalzulli E, Molica M, Alunni Fegatelli D, Colafigli G, Rizzo L, Mancini M, Efficace F, Latagliata R, Foà R, Breccia M. Scalzulli E, et al. Among authors: mancini m. Ann Hematol. 2019 Aug;98(8):1919-1925. doi: 10.1007/s00277-019-03724-9. Epub 2019 Jun 5. Ann Hematol. 2019. PMID: 31168652
2,393 results